Supplementary Table 1 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1

Eitemau Tebyg

• Supplementary Table 2 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
  gan: Caroline Robert (15032672)
  Cyhoeddwyd: (2025)
• Supplementary Table 3 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
  gan: Caroline Robert (15032672)
  Cyhoeddwyd: (2025)
• Supplementary Table 4 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
  gan: Caroline Robert (15032672)
  Cyhoeddwyd: (2025)
• Supplementary Table S1 from Intratumoral CD16⁺ Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
  gan: Hansol Lee (15054787)
  Cyhoeddwyd: (2025)
• Supplementary Table S2 from Intratumoral CD16⁺ Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
  gan: Hansol Lee (15054787)
  Cyhoeddwyd: (2025)